$361 Million is the total value of SABBY MANAGEMENT, LLC's 71 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 116.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | SPDR S&P 500 ETFput | $177,023,000 | +497.7% | 5,500 | +451.1% | 49.08% | +207.5% | |
| Buy | SPDR S&P 500 ETFcall | $52,013,000 | +247.1% | 1,616 | +220.0% | 14.42% | +78.6% | |
| New | SPDR GOLD TRput | $24,836,000 | – | 1,738 | +100.0% | 6.88% | – | |
| GLD | New | SPDR GOLD TR | $5,366,000 | – | 37,550 | +100.0% | 1.49% | – |
| Buy | AMARIN CORP PLCcall | $4,365,000 | +50.3% | 2,036 | +6.3% | 1.21% | -22.7% | |
| New | SPDR S&P BIOTECHcall | $3,662,000 | – | 385 | +100.0% | 1.02% | – | |
| ONTX | Buy | ONCONOVA THERAPEUTICS INC | $3,348,000 | +390.9% | 8,741,243 | +988.8% | 0.93% | +152.2% |
| New | ARQULE INC COMcall | $1,541,000 | – | 772 | +100.0% | 0.43% | – | |
| New | NABRIVA THERAPEUTICS PLC | $1,367,000 | – | 1,035,667 | +100.0% | 0.38% | – | |
| New | SORRENTO THERAPEUTICS INCput | $1,173,000 | – | 3,471 | +100.0% | 0.32% | – | |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $1,114,000 | -19.5% | 538,359 | +12.8% | 0.31% | -58.6% |
| BPTH | New | BIO PATH HOLDINGS INC | $986,000 | – | 123,346 | +100.0% | 0.27% | – |
| New | BIOGEN INCcall | $831,000 | – | 28 | +100.0% | 0.23% | – | |
| Buy | ORAMED PHARMACEUTICALS INCput | $804,000 | +1769.8% | 1,562 | +1057.0% | 0.22% | +869.6% | |
| Buy | PLURISTEM THERAPEUTICS INCput | $708,000 | +956.7% | 1,796 | +903.4% | 0.20% | +444.4% | |
| Buy | AVEO PHARMACEUTICALS INCput | $673,000 | +35.1% | 10,851 | +84.1% | 0.19% | -30.2% | |
| Buy | TOP SHIPS INC | $639,000 | +11.7% | 799,212 | +291.3% | 0.18% | -42.5% | |
| BNTC | New | BENITEC BIOPHARMA LTDadr | $603,000 | – | 118,285 | +100.0% | 0.17% | – |
| PSTV | Buy | PLUS THERAPEUTICS INC | $562,000 | +44.5% | 234,124 | +106.1% | 0.16% | -25.7% |
| Buy | DIFFUSION PHARMACEUTICALS INC | $500,000 | -42.2% | 1,085,446 | +132.0% | 0.14% | -70.2% | |
| GHSI | New | GUARDION HEALTH SCIENCES INC | $439,000 | – | 1,993,929 | +100.0% | 0.12% | – |
| SNCA | New | SENECA BIOPHARMA INC | $378,000 | – | 381,487 | +100.0% | 0.10% | – |
| AIM | Buy | AIM IMMUNOTECH INC | $288,000 | +104.3% | 528,811 | +185.6% | 0.08% | +5.3% |
| EARS | Buy | AURIS MED HLDG LTD | $278,000 | -39.7% | 171,883 | +2.6% | 0.08% | -69.0% |
| RWLK | Buy | REWALK ROBOTICS LTD | $273,000 | -22.4% | 126,280 | +9.8% | 0.08% | -60.0% |
| NURO | New | NEUROMETRIX INC | $275,000 | – | 63,880 | +100.0% | 0.08% | – |
| OTLK | New | OUTLOOK THERAPEUTICS INC | $229,000 | – | 388,936 | +100.0% | 0.06% | – |
| PSTI | Buy | PLURISTEM THERAPEUTICS INC | $222,000 | +59.7% | 56,442 | +51.8% | 0.06% | -17.3% |
| New | AVEO PHARMACEUTICALS INCcall | $225,000 | – | 3,625 | +100.0% | 0.06% | – | |
| ABEO | New | ABEONA THERAPEUTICS INC | $197,000 | – | 60,361 | +100.0% | 0.06% | – |
| DMPI | Buy | DELMAR PHARMACEUTICALS INC | $153,000 | -70.9% | 1,226,022 | +28.9% | 0.04% | -85.2% |
| LPCN | New | LIPOCINE INC | $142,000 | – | 367,693 | +100.0% | 0.04% | – |
| New | AKERS BIOSCIENCES INC | $93,000 | – | 29,100 | +100.0% | 0.03% | – | |
| SRNE | New | SORRENTO THERAPEUTICS INC | $92,000 | – | 27,178 | +100.0% | 0.03% | – |
| AEZS | Buy | AETERNA ZENTARIS INC | $93,000 | +25.7% | 101,976 | +41.5% | 0.03% | -35.0% |
| ALT | Buy | ALTIMMUNE INC COM | $85,000 | +4.9% | 44,855 | +7.4% | 0.02% | -45.5% |
| SPHS | New | SOPHIRIS BIO INC | $68,000 | – | 42,378 | +100.0% | 0.02% | – |
| New | TENAX THERAPEUTICS INC | $61,000 | – | 43,164 | +100.0% | 0.02% | – | |
| RBZHF | New | REEBONZ HLDG LTD | $29,000 | – | 25,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TRUST UNIT | 37 | Q3 2023 | 49.1% |
| ISHARES TR | 35 | Q3 2023 | 52.2% |
| SPDR S&P BIOTECHNOLOGY | 32 | Q3 2022 | 12.8% |
| AMARIN CORP PLC | 30 | Q4 2021 | 2.0% |
| BIOGEN INC | 24 | Q1 2021 | 26.2% |
| SAREPTA THERAPEUTICS INC | 24 | Q3 2020 | 4.6% |
| BIOGEN INC | 23 | Q1 2021 | 13.7% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2020 | 6.2% |
| BRAINSTORM CELL THERAPEUTICS INC | 21 | Q3 2023 | 1.6% |
| VERTEX PHARMACEUTICALS INC | 20 | Q1 2018 | 12.6% |
View SABBY MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AGM GROUP HOLDINGS, INC. | January 10, 2023 | 627,936 | 2.6% |
| Bit Digital, Inc | January 10, 2023 | 3,166,917 | 3.8% |
| Cingulate Inc. | January 10, 2023 | 10 | 5.0% |
| Context Therapeutics Inc. | January 10, 2023 | 796,706 | 5.0% |
| HeartBeam, Inc. | January 10, 2023 | 271,788 | 3.4% |
| PharmaCyte Biotech, Inc. | January 10, 2023 | 934,456 | 5.0% |
| Rebus Holdings, Inc.Sold out | January 10, 2023 | 0 | 0.0% |
| TANTECH HOLDINGS LTD | January 10, 2023 | 41,500 | 0.6% |
| Quanergy Systems, Inc. | January 04, 2023 | 936,905 | 5.8% |
| TuanChe Ltd | January 04, 2023 | 2,384,713 | 10.0% |
View SABBY MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
View SABBY MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.